Checking how well a new risk grouping predicts outcomes in sudden lung blood clots
Studies a new risk grouping in adults with acute pulmonary embolism seen in emergency departments.
Key facts
- Who runs it
- Marmara University Pendik Training and Research Hospital
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Prognostic Value of 2026 AHA/ACC Clinical Categorization in Acute Pulmonary Embolism Patients Presenting to the Emergency Department
- Status
- Recruiting
- People taking part
- 600 people, planned
- Started
- 17 Apr 2026
- Expected to end
- Mar 2027
- Type of study
- Observational
- Treatments tested
- 2026 AHA/ACC Clinical Risk Categorization
- Record updated
- 4 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who come to the emergency department with a sudden blood clot in the lungs (acute pulmonary embolism). It studies how well a new risk grouping predicts problems within 30 days.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Acute pulmonary embolism confirmed on a CT scan of the lung arteries (CTPA) within 24 hours of arriving at the emergency department.
- Earlier treatment
- People who had a pulmonary embolism within the last 3 months cannot join.
Main reasons for not taking part
- Long-term high blood pressure in the lungs caused by old clots (CTEPH)
- Pregnancy
- Incomplete or unclear CT scan
- Pulmonary embolism within the past 3 months
- Unable to complete 30-day follow-up, for example no phone or address
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age >=18 years
- Confirmed acute PE on CT pulmonary angiography (CTPA) within 24 hours of ED presentation
- Informed consent obtained
- Ability to complete 30-day follow-up
Who cannot take part
- Prior PE within 3 months
- Chronic thromboembolic pulmonary hypertension (CTEPH)
- Age <18 years
- Pregnancy
- Incomplete CTPA or non-diagnostic imaging
- Refusal of informed consent
- Inability to complete 30-day follow-up (no phone/address)
This trial is currently available in Türkiye.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Background: The 2026 American Heart Association/American College of Cardiology (AHA/ACC) Pulmonary Embolism Guideline (Creager et al., Circulation 2026) introduced a novel five-category (A-E) clinical classification system with subcategories and an R modifier, replacing prior risk stratification frameworks. Prospective validation of this classification system using composite clinical outcomes is lacking. Objective: To evaluate the prognostic value of the 2026 AHA/ACC clinical categorization (Categories A-E plus R modifier) for predicting 30-day Major Adverse Pulmonary Embolism Events (MAPEE) in emergency department (ED) patients with acute pulmonary embolism (PE). Methods: Prospective observational cohort study conducted at Marmara University Faculty of Medicine Emergency Department, enrolling 600 consecutive adult patients with confirmed acute PE by computed tomography (CT) pulmonary angiography between April 2026 and January 2027. Primary outcome: MAPEE composite (all-cause mortality OR hemodynamic deterioration OR treatment escalation OR cardiopulmonary resuscitation) within 30 days. Secondary outcomes include area under the receiver operating characteristic curve (AUC) comparison with the European Society of Cardiology (ESC) 2019 risk stratification (exploratory), negative predictive value (NPV) of low-risk categories (A+B) for safe discharge, MAPEE trend across C1/C2/C3, and R modifier odds ratio. Statistical analysis: Jamovi v2.x. Reporting follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 2007 checklist.
The group in the trial
- Acute PE Cohort - AHA/ACC 2026 Categories A-E + R modifier
All consecutive adult patients presenting to the emergency department with confirmed acute pulmonary embolism, assigned to 2026 AHA/ACC clinical categories (A-E) plus right ventricular strain (R) modifier at presentation. No study intervention is assigned; all patients are treated per standard of care per treating clinician judgment.
Treatment: 2026 AHA/ACC Clinical Risk Categorization
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prognostic Value of the 2026 American Heart Association/American College of Cardiology (AHA/ACC) Clinical Categorization System (Categories A-E) for Predicting 30-Day Major Adverse Pulmonary Embolism Events (MAPEE) in Patients Presenting to the Emergency Department With Acute Pulmonary Embolism: A Prospective Observational Cohort Study
- Plain-language title
- Checking how well a new risk grouping predicts outcomes in sudden lung blood clotsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 4 September 2026